AKT1 and non-small cell lung carcinoma: In conclusion, we have demonstrated that the resveratrol derivative TMS could reduce gefitinib resistance in NSCLC cells and xenograft tumour tissues by blocking the PI3K/Akt and MAPK pathways by upregulating miR‐345 and 498.